6CM
IDYA icon

683 Capital Management’s IDEAYA Biosciences IDYA Stock Holding History

683 Capital Management’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-22,364
Closed -$168K – 162
2019
Q4 		$168K Buy
+22,364
New +$160K 0.02% 135

Other funds holding IDYA

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

683 Capital Management's IDYA Position: Q1 2020 in Review

683 Capital Management sold out of IDEAYA Biosciences (IDYA) in Q1 2020, closing a stake of 22,364 shares — an estimated $168K sold.

683 Capital Management first reported a position in IDYA in Q4 2019 and held it in 1 quarter. The position peaked at $168K in Q4 2019. 28 funds tracked by Wall St. Rank hold IDYA as of Q1 2020.

  • 683 Capital Management reported no remaining IDEAYA Biosciences position as of Q1 2020 after selling out during the quarter.
  • 683 Capital Management sold 22,364 IDEAYA Biosciences shares in Q1 2020, an estimated $168K.
  • 683 Capital Management first reported a position in IDEAYA Biosciences in Q4 2019 and held it in 1 quarter.
  • 683 Capital Management's IDEAYA Biosciences position peaked at $168K in Q4 2019.
  • 28 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q1 2020.

Based on 683 Capital Management's 13F filing for Q1 2020, filed 15 May 2020.